Similar design of bi-functional degraders induce degradation of BCR-Abl [58] and Bruton’s tyrosine kinase (BTK) [59], showing therapeutic potentials in the treatment of chronic myeloid leukemia (CML) and B-cell lymphoma, respectively. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.